This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Snodgrass, S.R. Articles by Parks, B. R. Search for Related Content PubMed PubMed Citation Articles by Snodgrass, S.R. Articles by Parks, B. R. Social Bookmarking                         What's this?

Anticonvulsant Blood Levels: Historical Review With a Pediatric Focus

University of Mississippi Medical Center School of Medicine, Departments of Pediatrics and Neurology and School of Pharmacy, Department of Pharmacy Practice, Jackson, MS

Bruce R. Parks, PhD

University of Mississippi Medical Center School of Medicine, Departments of Pediatrics and Neurology and School of Pharmacy, Department of Pharmacy Practice, Jackson, MS

Epilepsy is heterogeneous and its treatment is often complicated by variable drug responses. Buchtal et al reported a close correlation between serum phenytoin levels, electroencephalographic fmdings, and clinical status in 1960. They suggested that physicians adjust dosage to attain a "therapeutic level." The concept was enthusiastically received. "Therapeutic serum levels" were proposed for most anticonvulsant drugs, and by 1975, most authorities believed that pharmacokinetic factors explained individual differences in drug response. However, Froscher found that measuring levels did not improve patient outcome. More recently, Schumacher's double-blind study found no correlation between phenytoin levels and seizure control or adverse effects. Pharmacodynamic variables (differences in drug responsiveness) are more important than pharmacokinetic factors for many drugs, especially receptor-active drugs. Pharmacokinetic variables were studied first, and led to a simplistic model. They are less significant than pharmacodynamic factors in the case of warfarin anticoagulation. Anticonvulsant levels can reveal noncompliance and pharmacokinetic differences. They say nothing about pharmacodynamics. Reports of "subtherapeutic levels" imply a need to increase dosage, but this is not supported by outcome data. We still lack evidence that specific drug levels are a valid intermediate target 40 years after Buchtal's paper. Responses to some anticonvulsants could depend primarily on pharmacokinetic factors, while pharmacodynamic factors could be supreme for others. (J Child Neurol 2000;15:734-746).

Journal of Child Neurology, Vol. 15, No. 11, 734-746 (2000)
DOI: 10.1177/088307380001501105


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				H. L. Falik AAP News, February 1, 2001; 18(2): 52 - 53. [Full Text] [PDF]